Skip to content

'A one-day diagnostic track for lung cancer suspects from chest X-ray using PET-CT and subsequent multiple endoscopic investigations. (including bronchoscopy, EUS-FNA and EBUS-TBNA)'.

'A one-day diagnostic track for lung cancer suspects from chest X-ray using PET-CT and subsequent multiple endoscopic investigations. (including bronchoscopy, EUS-FNA and EBUS-TBNA)'. - Fast-track diagnosis for lung cancer suspects with PET-CT and EUS-EBUS.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29952
Enrollment
100
Registered
2006-08-29
Start date
2006-09-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fast diagnosis of lung cancer suspects. one-day diagnostic tracking for lung cancer suspects

Interventions

One-day diagnostic track using PET-CT eventually with bronchoscopy, EUS-FNA , EBUS-TBNA and ultrasound guided transcutaneous biopsies.

Sponsors

Isala Klinieken
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with suspicion of lung cancer on chest X-ray. age between 18-85. informed consent.

Exclusion criteria

Exclusion criteria: comorbidity ( alcoholabuse, drugsabuse, limiting psychiatric illness ) non-compliance previous diagnostic tests for the suspicious chest X-ray (endoscopy, CT)

Design outcomes

Primary

MeasureTime frame
1. Number of patients that will have a definitive diagnosis and final stage NSCLC in one day. 2. Time between chest X-ray with suspicion on lung cancer and the first visit to the outpatient clinic. 3. Time between the first outpatient clinical contact and informing patient about definite diagnosis. 4. Time from the definite diagnosis until the initiation of therapy.

Secondary

MeasureTime frame
1. Number of patients able to have all diagnostic tests in one-day. 2. Number of tests and procedures that have been performed. 3. Patient satisfaction with the one-day procedure. 4. Sensitivity of EUS-FNA and EBUS-TBNA when immunohistochemical analysis is added to investigate false negative procedures.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)